Ticker

Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at higher doses, with Astellas providing $335M upfront and up to $1.37B in milestones. Recent licensing deals and a strong cash position ($781.6M) help offset 2025 net loss of $(438M), while pipeline advances target HDV and…

Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug.

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechnology retaining option to co-promote, and Astellas will obtain exclusive rights to commercialize VIR-5500 ex-U.S. - - Vir Biotechnology will receive $335M in upfront and near-term milestone payments, will split  U.S.…

Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue selling the product in the United States.

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) shares passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $13.56 and traded as high as $14.55. Astellas Pharma shares last traded at $14.11, with a volume of 118,178 shares. Analysts Set New Price Targets A number